Comparison on Hepatocarcinoma Model Induced by Diethylnitrosamine in Apc-mutant Rat and F344 Rat

doi:10.3969/j.issn.1674-5817.2017.03.004

Abstract

Abstract: Objective To establish hepatocarcinoma models induced by diethylnitrosamine (DEN) in F344 rats, KAD (Kyoto Apc Delta) rats and compare the advantages and disadvantages between them. Methods Twenty-five KAD rats were randomly divided into 2 groups. The 5 rats in control group were given the normal water. The 20 rats in experimental group were given the water containing 40 μg/mL DEN for 5 weeks, and the remaining 15 weeks they were given the normal water. Every 4 weeks, part of KAD rats was sacrificed to undergo pathological examination and make pathological sections of liver tissues and tumor tissues. Twenty-five F344 rats were treated the same as KAD rats. Results Hepatocarcinoma could be induced successfully in KAD rats and F344 rats. The same pathological developing process was found in them, which was similar with human. The average of 1.00±0.82 grey-white lesions could be found in 3 KAD rats (3/4) when they were induced in the 16th week, while no lesions could be found in F344 rats (0/4) at that time. Until the end of the experiments (20 weeks), 3.50 ±1.29 cancers and gray-white lesions had been developed in KAD rats, while only 1.25±0.96 could be found in F344 rats. The success rate of hepatocarcinoma induction in KAD rats was better than that in F344 rats significantly (P<0.05). Conclusion Comparing to F344 rats, KAD rats could be a better hepatocarcinoma induction model, with shorter induction time, higher sucess rate and numbers of hepatocarcinoma. KAD rat may be an ideal model for dynamically researching the hepatocarcinoma induction.

Key words: KAD rat, F344 rat, Hepatocarcinoma induction, Diethylnitrosamine (DEN)

CLC Number:

Q95-33

XIE Bei, ZHAO Lei, SUN Jing, ZHANG Li-juan, KURAMOTO Takashi, WEI Hu-lai. Comparison on Hepatocarcinoma Model Induced by Diethylnitrosamine in Apc-mutant Rat and F344 Rat[J]. Laboratory Animal and Comparative Medicine, 2017, 37(3): 191-197.

References

[1] Heindryckx F, Colle I, Van Vlierberghe H.Experimental mouse models for hepatocellular carcinoma research[J]. Int J Exp Pathol, 2009, 90(4):367-386.
[2] Wu L, Tang ZY, Li Y.Experimental models of hepatocellular carcinoma: developments and evolution[J]. J Cancer Res Clin Oncol, 2009, 135(8):969-981.
[3] Cortinovis C, Klimek F, Nogueira E.Rat hepatocarcinogenesis induced by N-nitrosodiethylamine and N-nitrosomorpholine continuously administered at low doses[J]. Am J Pathol, 1991, 139(5):1157-1171.
[4] Tanaka T, Kojima T, Kawamori T, et al.Chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis by a simple phenolic acid protocatechuic acid in rats[J]. Cancer Res, 1993, 53(12):2775-2779.
[5] Okubo H, Moriyama M, Tanaka N, et al.Detection of serum and intrahepatic hepatocyte growth factor during DEN-induced carcinogenesis in the rat[J] . Hepatol Res, 2002, 24(4):385-394.
[6] Jayaprakash R, Ramesh V, Sridhar MP, et al.Antioxidant activity of ethanolic extract of Tinospora cordifolia on N-nitrosodiethylamine (diethylnitrosamine) induced liver cancer in male Wistar albino rats[J] . J Pharm Bioallied Sci, 2015, 7(Suppl 1):S40-S45.
[7] Ma G, Bai R, Jiang H, et al.Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging[J]. Biomed Res Int, 2013, 813174.
[8] Yoshimi K, Tanaka T, Takizawa A, et al.Enhanced colitis-associated colon carcinogenesis in a novel Apc mutant rat[J]. Cancer Sci, 2009, 100(11):2022-2027.
[9] Tanaka T, Shimizu M, Kochi T, et al.Apc-mutant Kyoto Apc Delta (KAD) rats are susceptible to 4-NQO-induced tongue carcinogenesis[J]. Cancers (Based), 2014, 6(3):1522-1539.
[10] Yoshimi K, Tanaka T, Serikawa T, et al.Tumor suppressor APC protein is essential in mucosal repair from colonic inflammation through angiogenesis[J]. Am J Pathol, 2013, 182(4):1263-1274.
[11] Irving AA, Yoshimi K, Hart ML, et al.The utility of Apc-mutant rats in modeling human colon cancer[J] . Dis Model Mech, 2014, 7(11):1215-1225.
[12] Yoshimi K, Hashimoto T, Niwa Y, et al.Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay[J] . BMC Cancer, 2012, 12:448.
[13] Newell P, Villanueva A, Friedman SL, et al.Experimental models of hepatocellular carcinoma[J]. J Hepatol, 2008, 48(5):858-879.
[14] Hoshida Y, Fuchs BC, Tanabe KK.Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges[J] . Curr Cancer Drug Targets, 2012, 12(9):1129-1159.
[15] Park ST, Jang JW, Kim GD, et al.Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis[J]. Cancer Chemother Pharmacol, 2010, 65(6):1029-1037.
[16] De Minicis S, Kisseleva T, Francis H, et al.Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma[J]. Dig Liver Dis, 2013, 45(6):450-459.
[17] Colnot S, Decaens T, Niwa-Kawakita M, et al.Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinoma[J]. Proc Natl Acad Sci U S A, 2004, 101(49):17216-17221.
[18] Thompson MD, Monga SP.WNT/β-catenin signaling in liver health and disease[J] . Hepatology, 2007, 45(5):1298-1305.
[19] Shang N, Arteaga M, Zaidi A, et al.FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis[J]. Hepatology, 2015, 61(1):214-226.
[20] Hoshida Y, Nijman SM, Kobayashi M, et al.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J]. Cancer Res, 2009, 69(16):7385-7392.
[21] Liu LJ, Xie SX, Chen YT, et al.Aberrant regulation of Wnt signaling in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(33):7486-7499.